• Je něco špatně v tomto záznamu ?

Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

T. Moriyama, S. Liu, J. Li, J. Meyer, X. Zhao, W. Yang, Y. Shao, R. Heath, A. Hnízda, WL. Carroll, JJ. Yang,

. 2019 ; 18 (10) : 1887-1895. [pub] 20190729

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023650

Grantová podpora
P30 CA021765 NCI NIH HHS - United States
P50 GM115279 NIGMS NIH HHS - United States
R01 GM118578 NIGMS NIH HHS - United States

Relapse remains a formidable challenge for acute lymphoblastic leukemia (ALL). Recently, recurrent mutations in NT5C2 were identified as a common genomic lesion unique in relapsed ALL and were linked to acquired thiopurine resistance. However, molecular mechanisms by which NT5C2 regulates thiopurine cytotoxicity were incompletely understood. To this end, we sought to comprehensively characterize the biochemical and cellular effects of NT5C2 mutations. Compared with wild-type NT5C2, mutant proteins showed elevated 5'-nucleotidase activity with a stark preference of thiopurine metabolites over endogenous purine nucleotides, suggesting neomorphic effects specific to thiopurine metabolism. Expression of mutant NT5C2 mutations also significantly reduced thiopurine uptake in vitro with concomitant increase in efflux of 6-mercaptopurine (MP) metabolites, plausibly via indirect effects on drug transporter pathways. Finally, intracellular metabolomic profiling revealed significant shifts in nucleotide homeostasis induced by mutant NT5C2 at baseline; MP treatment also resulted in global changes in metabolomic profiles with completely divergent effects in cells with mutant versus wild-type NT5C2. Collectively, our data indicated that NT5C2 mutations alter thiopurine metabolism and cellular disposition, but also influence endogenous nucleotide homeostasis and thiopurine-induced metabolomic response. These complex mechanisms contributed to NT5C2-mediated drug resistance in ALL and pointed to potential opportunities for therapeutic targeting in relapsed ALL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023650
003      
CZ-PrNML
005      
20201214130723.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1535-7163.MCT-18-1112 $2 doi
035    __
$a (PubMed)31358663
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moriyama, Takaya $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. takaya.moriyama@stjude.org jun.yang@stjude.org.
245    10
$a Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia / $c T. Moriyama, S. Liu, J. Li, J. Meyer, X. Zhao, W. Yang, Y. Shao, R. Heath, A. Hnízda, WL. Carroll, JJ. Yang,
520    9_
$a Relapse remains a formidable challenge for acute lymphoblastic leukemia (ALL). Recently, recurrent mutations in NT5C2 were identified as a common genomic lesion unique in relapsed ALL and were linked to acquired thiopurine resistance. However, molecular mechanisms by which NT5C2 regulates thiopurine cytotoxicity were incompletely understood. To this end, we sought to comprehensively characterize the biochemical and cellular effects of NT5C2 mutations. Compared with wild-type NT5C2, mutant proteins showed elevated 5'-nucleotidase activity with a stark preference of thiopurine metabolites over endogenous purine nucleotides, suggesting neomorphic effects specific to thiopurine metabolism. Expression of mutant NT5C2 mutations also significantly reduced thiopurine uptake in vitro with concomitant increase in efflux of 6-mercaptopurine (MP) metabolites, plausibly via indirect effects on drug transporter pathways. Finally, intracellular metabolomic profiling revealed significant shifts in nucleotide homeostasis induced by mutant NT5C2 at baseline; MP treatment also resulted in global changes in metabolomic profiles with completely divergent effects in cells with mutant versus wild-type NT5C2. Collectively, our data indicated that NT5C2 mutations alter thiopurine metabolism and cellular disposition, but also influence endogenous nucleotide homeostasis and thiopurine-induced metabolomic response. These complex mechanisms contributed to NT5C2-mediated drug resistance in ALL and pointed to potential opportunities for therapeutic targeting in relapsed ALL.
650    _2
$a 5'-nukleotidasa $x metabolismus $7 D015720
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a chemorezistence $7 D019008
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a merkaptopurin $x chemie $x farmakologie $x terapeutické užití $7 D015122
650    _2
$a metabolomika $7 D055432
650    _2
$a biologické modely $7 D008954
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x enzymologie $x patologie $7 D054198
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Liu, Shuguang $u Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
700    1_
$a Li, Jing $u Department of Oncology, Pharmacology Core, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.
700    1_
$a Meyer, Julia $u Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, California.
700    1_
$a Zhao, Xujie $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
700    1_
$a Yang, Wentao $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
700    1_
$a Shao, Youming $u Protein Production Center, St. Jude Children's Hospital, Memphis, Tennessee.
700    1_
$a Heath, Richard $u Protein Production Center, St. Jude Children's Hospital, Memphis, Tennessee.
700    1_
$a Hnízda, Aleš $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Carroll, William L $u New York University Cancer Institute, New York University Langone Medical Center, New York, New York. Department of Pathology, New York University Langone Medical Center, New York, New York. Department of Pediatrics, New York University Langone Medical Center, New York, New York.
700    1_
$a Yang, Jun J $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. takaya.moriyama@stjude.org jun.yang@stjude.org. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
773    0_
$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 18, č. 10 (2019), s. 1887-1895
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31358663 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130722 $b ABA008
999    __
$a ok $b bmc $g 1595969 $s 1114326
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 10 $d 1887-1895 $e 20190729 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616
GRA    __
$a P30 CA021765 $p NCI NIH HHS $2 United States
GRA    __
$a P50 GM115279 $p NIGMS NIH HHS $2 United States
GRA    __
$a R01 GM118578 $p NIGMS NIH HHS $2 United States
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace